DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationMRCS

Thrombotic microangiopathy, HUS and TTP

Essential points for quick revision.

!
Escalate

Suspected TTP is a same-hour haematological emergency: send a pre-treatment ADAMTS13 sample, contact the designated regional TTP centre and begin the agreed plasma-exchange pathway without waiting for the result. Seizure, focal neurology, myocardial ischaemia, severe AKI, pregnancy-associated TMA and uncontrolled hypertension require parallel organ support and critical-care escalation.

Synopsis

Recognise microangiopathic haemolysis with thrombocytopenia as an emergency, obtain decisive samples without delaying therapy, and separate TTP, STEC-HUS, complement-mediated HUS and secondary thrombotic microangiopathies.

  • Thrombotic microangiopathy is a clinicopathological syndrome of small-vessel endothelial injury, microangiopathic haemolytic anaemia, thrombocytopenia and organ ischaemia; it is not a final aetiological diagnosis.
  • The laboratory pattern is falling haemoglobin and platelets, schistocytes, raised LDH and indirect bilirubin, reticulocytosis and low haptoglobin. The direct antiglobulin test is usually negative and coagulation may be relatively preserved in TTP.
  • Do not wait for the historical pentad of fever, neurological change, renal impairment, anaemia and thrombocytopenia. Many patients have only MAHA and thrombocytopenia when life-saving treatment should start.

Key red flags

Microangiopathic haemolysis

Anaemia, thrombocytopenia and fragmented red cells occur with high LDH, low haptoglobin, indirect hyperbilirubinaemia and a marrow reticulocyte response. Severe hypertension and mechanical valves can mimic parts of this pattern.

Investigation priorities

01
FBC, blood film and haemolysis profileFirst step

Demonstrate thrombocytopenia and non-immune red-cell fragmentation quickly and trend severity.

Management branches

Probable TTPSample, call and exchange

MAHA and thrombocytopenia have no immediately dominant alternative, especially with cerebral or cardiac features.

  1. Send citrate plasma for ADAMTS13 activity and inhibitor before any plasma if this causes no delay, plus urgent haemolysis, renal, coagulation, troponin and infection tests.
  2. Contact the designated regional TTP centre immediately and begin daily plasma exchange, corticosteroid and caplacizumab treatment under its protocol while arranging monitored transfer.

Key medicines

Therapeutic plasma exchangeExchange approximately one to one-and-a-half plasma volumes daily using the regional TTP centre protocol.
CaplacizumabGive 10 mg intravenously before first plasma exchange, then 10 mg subcutaneously after each exchange and daily for 30 days after exchange ends, with specialist extension if needed.
Open full textbook Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom